Drugmaker Pfizer said July 28 that data suggest a third dose of its COVID-19 vaccine provides a strong boost in protection against the highly contagious delta coronavirus variant.
The company said in an earnings report that initial findings suggest antibody levels against the delta variant were five times higher among people ages 18 to 55 and 11 times higher among those ages 65 to 85 after the third dose of its vaccine compared to after the second dose.
It also said there’s a potential for an up to “100-fold increase in delta neutralization” after a
third dose.
https://www.kansascity.com/news/coronavirus/article253082873.html
